腔内应用恩度和顺铂治疗恶性胸腔积液疗效及安全性临床研究

The clinical observation and safety of intrapleural injection of endostar combined with cisplatin in treatment of malignant pleural effusion

目的研究重组人血管内皮抑制素(恩度)联合顺铂(DDP)腔内注射治疗恶性胸腔积液的临床疗效和不良反应。方法随机对照观察46例恶性胸腔积液患者的腔入治疗情况,其中恩度联和顺铂组(A组)21例,单纯顺铂组(B组)25例;3次为1个疗程。1个疗程结束后进行疗效评价,非PD的患者再进行1个疗程,腔内应用2个疗程后再次评效,进行对照观察。结果 A组总有效率为61.90%,B组总有效率为44.00%,两组比较,差异有统计学意义(P<0.05);A组总的不良反应率为38.10%,B组总的不良反应率为32.00%,两组比较差异无统计学意义(P>0.05)。结论恩度联合顺铂腔内注射治疗恶性胸腔积液的临床疗效较单药顺铂略有提高,而不良反应未见明显增加,值得临床进一步推广研究。

Objective To evaluate the clinical efficacy and adverse reactions of Endostar combined with cisplatin in the treatment of malignant pleural effusion. Methods 46 cases with malignant pleural effusion were divided into two groups. the A group（endostar combined with cisplatin）, 21 cases, were given endostar and DDP; the B group（cisplatin alone）, 25 cases, were given with cavity injection DDP; 3 times for a course. To evaluate the efficacy after the end of a course and the patients with non-progress were given the second treatment. Results The total effective rates in A group was 61.90%, the B group was 44.00%. The difference was statistically significant（P〈0.05）. The rate of adverse reactions in A group was 38.10%, the A group was 32.00%, the difference was not statistically significant（P〉0.05）. Conclusion It is a safe and feasible way to treat malignant pleural effusion with Endostar combined with cisplatin.